OR WAIT null SECS
has introduced a new
study simulation and forecasting service
that will enable clinical trial sites to better plan and control supplies for their patients. When integrated with Cenduit’s interactive response technology (IRT) services, the new service will give sponsors complete confidence in their clinical supply chain.
“Clinical trials are more complex than ever and a robust and reliable clinical trial supply strategy is vital to study success,” said Jogin Desai, Cenduit chief executive officer. “The simulation and forecasting models, integrated with the
services inherent in our IRT systems, allow the complete coordination of procurement, packaging and logistics, with supply requirements from the sites themselves continuously factored in.”
Desai said the new system helps further minimize the risk of drug supply overage and drug outages at sites and accelerates drug development through increased supply chain productivity. The system also allows clinical trial supply coordinators to test different supply scenarios before implementing them, and to identify in advance the risks associated with any supply strategy.
“By integrating forecasting and simulation parameters into the IRT system, patients will receive the right treatment on time, every time and at the lowest cost,” Desai said.